A MAJOR ALZHEIMER'S PREVENTION TRIAL HAS RANDOMIZED ITS FIRST PARTICIPANT.
The study will test whether clearing amyloid, then adding a second mechanism, can delay inherited Alzheimer's.
The Alzheimer's Prevention Initiative's new autosomal-dominant Alzheimer's trial has assigned its first participant, moving a long-planned prevention strategy into randomized testing.
WHAT HAPPENED
Researchers will first use donanemab to remove amyloid plaque, then test nivagacetor alone, the combination, or placebo in members of a Colombian family carrying the PSEN1 E280A mutation. Carriers face near-certain early-onset Alzheimer's, making prevention studies possible years before symptoms.
WHY THIS IS HOPESLOP
There is no cure to celebrate here. The hope is the rigor: a high-risk community, a two-stage design, and the resources to ask whether intervening before dementia can actually change the disease's course.
ORIGINAL SOURCEBanner HealthRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.